W-L Expects Neurontin Sales To Reach $800 Mil. And Hold Through 2000
Executive Summary
Warner-Lambert expects its anti-epileptic product Neurontin (gabapentin) to grow by more than 50% to $800 mil. this year and hold that level through its patent expiration year of 2000, the company said at a May 18 meeting with the New York Society of Securities Analysts.